U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339839) titled 'Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC' on Jan. 05.
Brief Summary: This study evaluates the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase II dose (RP2D) of Glecirasib in combination with Ivonescimab in patients with previously untreated, KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 TPS >=1%. The study includes a Phase I 3+3 dose-escalation stage followed by a Phase II Simon two-stage design to assess preliminary antitumor efficacy.
Study Start Date: March 01
Study Type: I...